Battelino, T.* ; Lalic, N.* ; Hussain, S.* ; Ceriello, A.* ; Klobucar, S.* ; Davies, S.J.* ; Topsever, P.* ; Heverly, J.* ; Ulivi, F.* ; Brady, K.* ; Tankova, T.* ; Galhardo, J.* ; Tagkalos, K.* ; Werson, E.* ; Mathieu, C.* ; Schwarz, P.E.
The use of continuous glucose monitoring in people living with obesity, intermediate hyperglycemia or type 2 diabetes.
Diabetes Res. Clin. Pract. 223:112111 (2025)
A global trend towards increased obesity, intermediate hyperglycemia (previously termed prediabetes) and type 2 diabetes, has prompted a range of international initiatives to proactively raise awareness and provide action-driven recommendations to prevent and manage these linked disease states. One approach, that has shown success in managing people already diagnosed with type 2 diabetes mellitus, is to use continuous glucose monitoring (CGM) devices to help them manage their chronic condition through understanding and treating their daily glucose fluctuations, in assocation with glucose-lowering medications, including insulin. However, much of the burden of type 2 diabetes mellitus is founded in the delayed detection both of type 2 diabetes mellitus itself, and the intermediate hyperglycaemia that precedes it. In this review, we provide evidence that using CGM technology in people at-risk of intermediate hyperglycaemia or type 2 diabetes mellitus can significantly improve the rate and timing of detection of dysglycaemia. Earlier detection allows intervention, including through continued use of CGM to guide changes to diet and lifestyle, that can delay or prevent harmful progression of early dysglycaemia. Although further research is needed to fully understand the cost-effectiveness of this intervention in people at-risk or with early dysglycemia, the proposition for use of CGM technology is clear.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
Publication type
Article: Journal article
Document type
Review
Thesis type
Editors
Keywords
Consensus Statements ; Continuous Glucose Monitoring ; Intermediate Hyperglycemia ; Obesity ; Prediabetes ; Type 2 Diabetes; Life-style Intervention; Follow-up; Glycemic Variability; Microvascular Complications; Severe Hypoglycemia; Insulin Injections; Consensus Report; Time; Association; Risk
Keywords plus
Language
english
Publication Year
2025
Prepublished in Year
0
HGF-reported in Year
2025
ISSN (print) / ISBN
0168-8227
e-ISSN
1872-8227
ISBN
Book Volume Title
Conference Title
Conference Date
Conference Location
Proceedings Title
Quellenangaben
Volume: 223,
Issue: ,
Pages: ,
Article Number: 112111
Supplement: ,
Series
Publisher
Elsevier
Publishing Place
Elsevier House, Brookvale Plaza, East Park Shannon, Co, Clare, 00000, Ireland
Day of Oral Examination
0000-00-00
Advisor
Referee
Examiner
Topic
University
University place
Faculty
Publication date
0000-00-00
Application date
0000-00-00
Patent owner
Further owners
Application country
Patent priority
Reviewing status
Peer reviewed
Institute(s)
Institute of Pancreatic Islet Research (IPI)
POF-Topic(s)
90000 - German Center for Diabetes Research
Research field(s)
Helmholtz Diabetes Center
PSP Element(s)
G-502600-004
Grants
Medical Research Council Clinical Academic Partnership award
Slovenian Research and Inovation Agency
Copyright
Erfassungsdatum
2025-05-09